119 related articles for article (PubMed ID: 27010394)
41. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
42. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
[TBL] [Abstract][Full Text] [Related]
43. [Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel].
Terada M; Sugiura H; Yoshimoto N; Nishikawa S; Ito Y; Kawaguchi Y; Ando Y; Hato Y
Gan To Kagaku Ryoho; 2017 Jul; 44(7):591-593. PubMed ID: 28790263
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
45. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
46. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Dieras V; Pop S; Berger F; Dujaric ME; Beuzeboc P; Escalup L; Bidard FC; Cottu PH; LE Tourneau C; Piperno-Neumann S; Laurence V; Robain M; Asselain B; Pierga JY
Anticancer Res; 2017 Mar; 37(3):1403-1407. PubMed ID: 28314310
[TBL] [Abstract][Full Text] [Related]
47. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.
Sanna G; Fabi A; Crivellari D; Saracchini S; Battelli N; Nisticò C; Capobianco AM; Zampa G; Bottini A; Del Prete S; Simoncini E; Galli A; Matasconi M; Restuccia E; Biganzoli L
Tumori; 2014; 100(4):432-8. PubMed ID: 25296593
[TBL] [Abstract][Full Text] [Related]
50. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
51. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Ray-Coquard IL; Domont J; Tresch-Bruneel E; Bompas E; Cassier PA; Mir O; Piperno-Neumann S; Italiano A; Chevreau C; Cupissol D; Bertucci F; Bay JO; Collard O; Saada-Bouzid E; Isambert N; Delcambre C; Clisant S; Le Cesne A; Blay JY; Penel N
J Clin Oncol; 2015 Sep; 33(25):2797-802. PubMed ID: 26215950
[TBL] [Abstract][Full Text] [Related]
52. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Grasselli G; Viganò L; Capri G; Locatelli A; Tarenzi E; Spreafico C; Bertuzzi A; Giani A; Materazzo C; Cresta S; Perotti A; Valagussa P; Gianni L
J Clin Oncol; 2001 Apr; 19(8):2222-31. PubMed ID: 11304775
[TBL] [Abstract][Full Text] [Related]
53. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer.
Romero Acuña L; Langhi M; Pérez J; Romero Acuña J; Machiavelli M; Lacava J; Vallejo C; Romero A; Fasce H; Ortiz E; Grasso S; Amato S; Rodríguez R; Barbieri M; Leone B
J Clin Oncol; 1999 Jan; 17(1):74-81. PubMed ID: 10458220
[TBL] [Abstract][Full Text] [Related]
54. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
55. [Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - A Case Report].
Nakayama I
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1391-1392. PubMed ID: 29394644
[TBL] [Abstract][Full Text] [Related]
56. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
Li T; Wang B; Wang Z; Ragaz J; Zhang J; Sun S; Cao J; Lv F; Wang L; Zhang S; Ni C; Wu Z; Xie J; Hu X
PLoS One; 2015; 10(7):e0133133. PubMed ID: 26186012
[TBL] [Abstract][Full Text] [Related]
57. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
[TBL] [Abstract][Full Text] [Related]
58. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
59. [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Nakazawa Y; Kageyama A; Harada D; Kitamura M; Mitsumori N; Kawakubo T
Gan To Kagaku Ryoho; 2019 May; 46(5):901-905. PubMed ID: 31189812
[TBL] [Abstract][Full Text] [Related]
60. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
